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SYSTEMATIC REVIEW
Patients with FLT3-mutant AML needed to enroll on FLT3-targeted
therapeutic clinical trials
Taylor Bucy,1,2 John M. Zoscak III,1,2 Motomi Mori,1,2 and Uma Borate1
1Knight Cancer Institute, Oregon Health & Science University, Portland, OR; and 2Oregon Health & Science University–Portland State University School of Public Health,
Portland, OR
We sought to identify the total number of therapeutic trials targeting FLT3-mutant acute
myeloid leukemia (AML) to estimate the number of patients needed to satisfy
recruitment when compared with the incidence of this mutation in the US AML
population. A systematic review of all therapeutic clinical trials focusing on adult
FLT3-mutated AML was conducted from 2000 to 2017. An updated search was performed
using ClinicalTrials.gov for trials added between October 2017 and December 2018.
Analysis was performed for ClinicalTrials.gov search results from 2000 to 2017 to
provide descriptive estimates of discrepancies between anticipated clinical trial
enrollment using consistently cited rates of adult participation of 1%, 3%, and 5%, as well
as 10% participation identified by the American Society of Clinical Oncology in 2008.
Twenty-five pharmaceutical or biological agents aimed at treating FLT3-mutant AML
were identified. Pharmaceutical vs cooperative group/nonprofit support was 2.3:1, with
30 different pharmaceutical collaborators and 13 cooperative group/nonprofit
collaborators. The number of patients needed to satisfy study enrollment begins to
surpass the upper bound of estimated participation in 2010, noticeably surpassing
projected participation rates between 2015 and 2016. The number of patients needed to
satisfy study enrollment surpasses 3% and 5% rates of historical participation for
US-only trials in 2017. We estimate that 15% of all US patients with FLT3-mutant AML
would have to enroll in US and internationally accruing trials to satisfy requirements in
2017, or approximately 3 times the upper level of historical participation rates in the
United States. The current clinical trial agenda in this space requires high percentage
enrollment for sustainability.
Introduction
In the present era of precision oncology, there is growing recognition that the number of patients needed
for enrollment in clinical trials investigating agents with similar mechanisms of action may be greater than
the number of patients with specific targetable mutations.1 The therapeutic approaches of precision
oncology and immuno-oncology have become more widely used, especially as advancements in
sequencing allow relatively inexpensive and rapid characterization of tumor tissue relevance.2,3 In tumor
types such as melanoma, the success of immunotherapy heralded by the approval of ipilimumab opened
the door for anti-PD-1/ PD-L1 and anti-CTLA-4/CTLA-4 directed therapy in multiple tumor types, and
the broad efficacy of this approach led to James P. Allison and Tasuku Honjo being awarded the
2018 Nobel Prize in Physiology and Medicine.4,5
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Despite tremendous success in targeting the immune system
across various cancers, a study by Tang et al noted 164 agents
targeting PD-1/PD-L1, with 50 of the 164 agents in clinical stages
(45 agents in phase I-III clinical trials, 5 approved).6 This highlights
the large number of similar agents being investigated in the absence
of head-to-head comparisons.6 The increasing number of clinical
trials investigating agents that target similar pathways has created
challenges for investigators, patients, and regulatory agents, and
has prompted some to suggest adjustments to current clinical trial
design and regulation.6,7 In addition, accrual requirements for
investigational studies often exceed the number of patients in an
eligible population harboring a particular tumor type or mutation.6
Several studies (Carlisle et al8 and Mattina et al9) have expressed
concern regarding redundant and duplicative trial agendas
in systematic reviews focusing on sunitinib and sorafenib,
respectively.8,9 Despite an abundance of trials using agents
that target the same or similar immune or molecular locations,
only 5% of clinically tested agents move toward approval by the
US Food and Drug Administration.10 This prompts a closer look
into the repercussions this may have on clinical trial participants
and the quality of this research.6,8-10
Acute myeloid leukemia (AML) is a hematologic malignancy with
growing identification of prognostically significant mutations with
the potential for therapeutic inhibition or alteration. AML comprises
1.3% of all new cancer diagnoses in the United States every year,
with an estimated 21380 new cases in 2017.11,12 Research and
clinical advances have allowed for further disease classification
and the generation of targeted therapies.13,14 One such
mutation that has gained attention is the FMS-like tyrosine
kinase 3 (FLT3) mutation.14-18 FLT3 mutations are deemed one
of a few “actionable” mutations, and occur in 30% of de novo
AML cases; 25% are internal tandem duplication (FLT3-ITD)
mutations, and 5% are tyrosine kinase domain mutations.11,15,16,19,20
A normally functioning FLT3 protein, after binding to its ligand FL
and undergoing phosphorylation, plays a role in the promotion of
cellular proliferation and anti-apoptotic activity, and influences
hematopoietic precursor cells.14,17 Both ITD and tyrosine kinase
domain mutations result in constitutive pathway activation via
a conformational change and interference with inhibitory effects of
the activation loop, respectively.14
With an estimated 21 380 new AML cases in 2017, approximately
5345 individuals will harbor FLT3-ITD mutations, and 1069 will
possess a tyrosine kinase domain mutation. Multiple small-molecule,
tyrosine/multikinase inhibitors have been developed for FLT3-mutated
AML.14,19-21 In April 2017, the tyrosine/multikinase inhibitor
midostaurin was the first such targeted agent approved by
the US Food and Drug Administration for the treatment of
FLT3-mutated AML, based on the findings of the phase 3
randomized CALGB 10603/RATIFY clinical trial.21,22 Most recently,
gilteritinib was approved for relapsed/refractory FLT3-mutant AML in
November 2018, based on the interim analysis results of the
ADMIRAL trial (NCT02421939). With the advancement of genetic
and molecular testing during the past decade, the focus on targeted
therapies for the treatment of AML has expanded.23,24 In turn,
this has led to more clinical trials focusing on specific molecular
mutations.11,12,23,24
The FLT3-mutated AML population was chosen to reflect on
a larger discussion within clinical hematology/oncology, specifically
the development and conduct of potentially duplicative clinical trials
in the United States. We sought to examine how many investiga-
tional FLT3 agents developed and studied in therapeutic clinical
trials targeted FLT3-mutated AML within a specified timeframe. We
hypothesized that therapeutic trials examining FLT3 inhibitors
require a sizable percentage of patients with FLT3-mutated AML,
and that the number of patients needed for recruitment to these
trials exceeds the number of eligible patients who are willing and
able to participate in clinical trials.
Methods
We conducted a systematic review of all therapeutic clinical trials
investigating FLT3 inhibitors targeting patients with FLT3-mutated
AML registered in ClinicalTrials.gov from 2000 to 2017. We sought
to estimate what percentage of patients with AML with FLT3
mutations would need to enroll in clinical trials to satisfy anticipated
recruitment needs each year during this period.
Methodology was guided by the PRISMA 2009 guidelines
(Figure 1; supplemental Appendices 1 and 2).25 We performed
an advanced search, using ClinicalTrials.gov to identify clinical trials
focusing on adult FLT3 AML from 1 January 2000 to 11 October
2017 (day of initial search). An additional search was then
performed in PubMed for adult FLT3 AML clinical trials cataloged
from 1 January 2000 to 31 December 2017. Duplicate removal and
a search for associated publications was performed using the
ClinicalTrials.gov identifier (NCT identifier) and official study title as
the primary and secondary identifiers, respectively (Figure 1).
Results produced from both the ClinicalTrials.gov and PubMed
searches were assessed for eligibility, and relevant variables
extracted. A complete methodology is described in supplemental
Appendix 2, with exclusionary criteria detailed in both Figure 1 and
supplemental Appendix 2D. After screening and eligibility assess-
ment, there were 78 therapeutic studies focusing on FLT3 AML
remaining, and an attempt was made to find abstract or full-article
publications for these trials. The 78 clinical trials and publications
were sorted into 4 groups: group A: newly diagnosed/treatment
naive; group B: relapsed/refractory; group C: newly diagnosed
and/or relapsed/refractory; and group D: other, nonspecific in-
clusion language. All unique pharmaceutical agents used for the
study of possible FLT3-mutant inhibition were subsequently
identified and confirmed through review of available literature.
An updated search was performed in ClinicalTrials.gov, using the
above-mentioned search criteria to account for studies posted
between 11 October 2017 and 31 December 2018. This produced
18 additional trials; however, only 7 met criteria for inclusion.
Analysis of trends in trial recruitment
Analysis was performed on all studies registered to ClinicalTrials.
gov from 2000 to 2017 that met criteria for inclusion, as detailed in
the methods (n 5 66). Accrual duration (D) was calculated using
the study start date and estimated primary completion date, with
variable D used to calculate the average number of patients needed
to be enrolled per year (Q) to correspond to the estimated or
completed enrollment number. If enrollment was ongoing, Q was
found by dividing estimated enrollment by accrual duration, D; if
enrollment was completed, the number of persons enrolled at
completion was used in place of estimated enrollment. The average
number of patients needed to be enrolled per year (Q) was used to
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estimate the average number of patients accrued in each year of
study (P; Table 1).
Analysis to identify trends in trial recruitment was performed to
provide estimates of discrepancies in anticipated clinical trial
enrollment. This was done using consistently cited rates of adult
clinical trial participation of 1%, 3%, and 5% vs the participant
recruitment needed to fulfill specified accrual numbers for primary
completion.26-28 The decision was made to exclude the 12 unique
publications available through the PubMed search, as study
duration was not consistently reported. The updated search
performed from October 2017 to December 2018 produced
7 additional studies that had not yet reached completion and are
also not included in statistical analysis.
Two assumptions were made for the analysis: accrual rate is
constant during the duration of the trial, and the rate of FLT3
mutations has been constant, at 30%, since 2000. Data were
obtained and analyzed using the Centers for Disease Control
and Prevention and Surveillance, Epidemiology, and End Results
databases; literature review; and Microsoft Excel.
Results
Descriptive findings
Of the 85 included trials and publications, the majority were phase
2 trials (n 5 27; 31.8%) and were actively recruiting (n 5 32;
37.6%) or completed (n 5 29, 34.1%; supplemental Appendix 3).
Twenty-five unique pharmaceutical or biological agents, either
known FLT3 inhibitors or investigational agents used with the intent
of targeting this molecular abnormality, were identified and
corroborated by literature review (Figure 2).19,29-52 Thirty different
pharmaceutical companies acted as collaborators or sole sponsors
Records identified through database
 searching (ClinicalTrials.gov) 
(n = 91) 
Additional records identified through 
other sources (PubMed) 
(n = 95) 
Records after duplicates removed 
(n = 173) 
PubMed full-text articles
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records
removed
(n = 25)
ClinicalTrials.gov records
screened
(n = 91)
- Remaining 12 PubMed records
  excluded due to
  inconsistent/incomplete
  reporting of study duration. 
-Updated ClinicalTrials.gov
  search results (n=7) excluded. 
Studies included in
 quantitative analysis
(n = 66) 
Studies included in
qualitative synthesis
(n = 85) 
Updated ClinicalTrials.gov search
 from 10/11/2017–12/31/2018:
(n = 7)
Exclusionary criteria
- Not interventional or therapeutically directed.
- Retrospective analyses, cytogenetic and/or mechanism
of action studies.
- Subjects 18 years of age. 
- No use of FLT3 inhibitor. 
- No use of a drug with intent of analyzing a FLT3 mutant
  populations' response.
- FLT3 mutants (ITD/TKD) are not the target population.
- Start date or enrollment prior to 01/01/2000. 
Figure 1. Flow diagram depicting the process of duplicate removal and screening per PRISMA 2009 guidelines.
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of these interventional studies (supplemental Appendix 3). Eighteen
studies did not list sponsorship/collaboration as coming from
a pharmaceutical company. Additional sponsors include the
academic universities acting as primary sites, as well as cooperative
groups, nonprofit and charitable foundations, and subdivisions of
the National Institutes of Health. Of the 30 unique pharmaceutical
companies offering sponsorship/collaboration, 25 were the phar-
maceutical developers of the proposed FLT3 inhibitors (Figure 2).
Pharmaceutical vs nonprofit/cooperative group involvement was
2.3:1. The most prominent pharmaceutical sponsorships were
Novartis (midostaurin, PKC 412) and Arog (crenolanib), which
sponsored/collaborated on 13 and 8 trials, respectively.
Representation of subgroups
These 85 studies were further divided into 4 groups on the basis of
language used in inclusion criteria: group A: newly diagnosed or
untreated (n5 19); group B: relapsed/refractory (n5 27); group C:
both newly diagnosed or relapsed/refractory (n5 11); and group D:
nonspecific language in their inclusion criteria (n 5 28), such as:
AML in complete remission, patients status after allogeneic stem
cell transplant, relapsed/refractory or unfit for induction because of
age/comorbidity/other factors per principal investigators discretion,
refusal of induction therapy, or AML for which no standard
treatment is available (supplemental Appendix 3). Interventional
studies represented both international and US sites: 44.4% of the
studies included in group A, 52% of the studies included in group B,
36.4% of the studies in group C, and 46.2% of the studies in
group D took place in the United States only.
Midostaurin, crenolanib, sorafenib, quizartinib, pacritinib, gilteritinib,
sunitinib, lestaurtinib, and SU5416 were used as an interventional
agent by more than 1 subgroup (supplemental Appendix 3).
Midostaurin was predominately used in trials aimed at targeting
newly diagnosed/untreated individuals (group A; n 5 9), and was
used a total of 8 times across the other 3 groups. Only 1 study
(NCT03258931) proposed a head-to-head comparison, exploring
the efficacy of midostaurin vs crenolanib. This randomized trial is
recruiting as of 15 August 2018, and plans to accrue 510 subjects;
estimated primary completion is in November 2022.
Trends in trial recruitment
The 66 ClinicalTrials.gov studies represent 33 US-only trials,
17 international-only trials, 13 studies active both at international
and US sites, and 3 trials for which no site location was available at
the time of data collection. Projected accrual is as follows: 3802
participants for the combined US and international studies
(includes the 3 trials with unlisted location), 2109 participants for
international-only trials, and 1704 participants for US-only trials.
Seventeen (25.8%) of the 66 registered trials were newly
diagnosed FLT3-mutant AML, and 19 (28.8%) of the 66 registered
trials were for relapsed/refractory FLT3-mutant AML. Total accrual
for newly diagnosed trials (n 5 17) was projected at 3432, with an
average of 201.88 patients per trial. Of the 17 newly diagnosed
trials, 8 were US only, 6 were international only, and 3 were both US
and international. Of the 19 relapsed/refractory trials, 11 were US
only, 5 were international only, and 3 were US 1 international.
Projected accrual mean and standard deviation for newly diagnosed
and relapsed/refractory trials are included in Table 2. Projected
accrual by trial phase for newly diagnosed and relapsed/refractory-
only trials is included in Table 3.
We used the study start dates and primary completion dates of all
66 clinical trials from ClinicalTrials.gov remaining after duplicate
Table 1. Methodology for analysis of the 66 studies registered to ClinicalTrials.gov from 2000 to 2017 that met criteria for inclusion
Process step Variable
Accrual duration (D) of each study from ClinicalTrials.gov D 5 (estimated primary completion date 2 study start date)/365.25
The average number of patients needed to be enrolled per year (Q) to
correspond to the estimated (or completed) enrollment number
Q 5 Estimated Enrollment (or completed enrollment)/D
Estimated average number of patients accrued in each year of study Pij 5 (Q / 12 mo) * number of months study accrual was active that year (Mi)
i 5 active year; j 5 NCT number.
Months were included in Mi for dates #15th and were excluded in Mi for dates .15th
Estimate for number of patients needed for enrollment in final study year Pij (last year of study) 5 Estimated (or Completed) Enrollment – Sum of all previous Pij
9
7
14
17
10
3
4
22
25 Pharmaceutical Agents in 85 Clinical Trials
Crenolanib
Quizartinib
Sorafenib
Lestaurtinib
Gilteritinib
Sunitinib
Midostaurin
Other
Figure 2. Unique pharmaceutical agents identified in search and used with
the intent of treating FLT3 AML.
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removal and screening to identify the duration of each trial. These
66 trials were identified in the initial search. Primary completion
date was chosen, as this was consistently reported across trials.
Incidence data were collected from the Centers for Disease Control
and Prevention and Surveillance, Epidemiology, and End Results
databases or from publications.53,54 These data were analyzed
within the context of the anticipated enrollment across all trials from
2000 to 2017, and contrasted with 1%, 3%, and 5%. clinical trial
participation rates. Historical clinical trial participation at 1%, 3%,
and 5% was chosen on the basis of evidence suggesting that 5%
or less of all individuals with cancer in the United States enroll
and partake in clinical studies.26-28 An additional bar depicting
projections for 10% clinical trial participation was added to
represent the potential for increased enrollment taking place
outside the United States and at National Cancer Center-
designated cancer centers, based on the American Society of
Clinical Oncology statement on minimum standards and exemplary
attributes of clinical trial sites.55
As seen in Figure 3A-B, the number of FLT3-positive patients
needed to satisfy study enrollment for FLT3-targeted therapeutic
trials begins to surpass the upper bound of estimated participa-
tion in 2010 and noticeably surpasses projected participation
rates between 2015 and 2016. Beginning with 2015 in Figure 3B
(US1 international trials), approximately 6.82% of all patients newly
diagnosed with FLT3-mutated AML would need to enroll in a clinical
trial to satisfy accrual for that year. In 2016, this grows to 10.88% of
all FLT3-mutated AML, and in 2017, this number grows to 14.76%,
or approximately 3 times the percentage of individuals with
any cancer type who will enroll in a clinical study. Enrollment
needs to satisfy recruitment surpassed a 10% participation rate
for US 1 international trials in 2016 (Figure 3B). The number of
patients needed to satisfy study enrollment surpassed 5%
estimated participation for US-only trials in 2017, and 3% estimated
participation in 2016 (Figure 3C).
Although it is possible that the inclusion of US-only as well as
US 1 international trials may confound our results, it is unlikely
to significantly alter our conclusions. Should trends in US-only
clinical trial recruitment needs continue, enrollment needs beyond
the available US patient population would need to come from
international locations. Thus, Figure 3C would show a bigger
discrepancy if the possibility of concurrent international and US
accrual were not considered.
Discussion
Despite the investment in targeted therapies for FLT3-mutated
AML, this distinct mutational subset only represents a quarter of all
de novo AML cases.11,15,16,19,20 According to our analysis,
approximately 15% of patients with FLT3-mutated AML in 2017
would have needed to participate in clinical trials to satisfy the
eligibility requirements of all therapeutic FLT3 inhibitor studies. The
current rate of clinical trial participation in the United States, at 3%
to 5%, is not reflected in our data or in the results of our subsequent
analysis.26 Given the heterogeneity of AML, it is not unlikely that the
future of clinical trial development will include combinations of
targeted agents. For example, IDH1 and IDH2 mutations co-occur
with FLT3-ITD mutations in 15% to 27% and 8% to 30% of cases,
respectively.56 With the approval of enasidenib (IDH2) and
ivosidenib (IDH1) in 2018 and 2019, respectively, targeted
combination trials may make more acute the difficulty in satisfying
enrollment projections. There is also the potential for our results to
underestimate the competition for patients with FLT3-mutant AML,
given that some trials (eg, NCT03092674) allow for the treatment
of both FLT3-mutant and FLT3-negative participants with a FLT3
inhibitor. Rates of participation may be slightly greater than 1% to
5% for AML if trials are recruiting mutant and wild-type participants
as well. Competition for FLT3-mutant trial participants may also
be enhanced by the promising clinical results of new therapies
that are not FLT3-targeted agents, such as those described in
the phase 1/2 results of the combination study of venetoclax
with azacytidine or decitabine (NCT02203773).57 Treatment of
FLT3-mutant patients under investigational protocols that do not
include a FLT3 inhibitor puts further strain on the ability of inhibitor
trials to fulfill accrual requirements.
Clinical trials in the era of precision medicine have led to the
investigation of multiple therapeutic agents targeting similar and/or
identical genomic variants or oncogenic pathways. One possible
effect of this biomedical advance is a smaller pool of patients who
harbor molecular or genetic abnormalities than may be eligible for
trial participation.1 There is also a concern that an abundance of
trials focusing on relatively narrow subsets of the population may
Table 2. Projected accrual, mean, and standard deviation for newly
diagnosed (n = 17, 25.8%) and relapsed/refractory (n = 19, 28.8%)
trials
Type and location n (%) Mean SD
Newly diagnosed
United States only 824 (24) 103 165.37
International only 1286 (38) 214.33 225.71
United States 1 international 1322 (39) 440.67 334.35
Total, N 3432
Relapsed/refractory
United States only 1025 (34) 73.21 79.45
International only 1073 (36) 214.60 150.11
United States 1 international 924 (31) 308 74.71
Total, N 3022
SD, standard deviation.
Table 3. Enrollment targets (United States only, international only,
international 1 United States)
Total projected enrollment
Newly diagnosed (n 5 17)
Phase 1 88
Phase 1/2 93
Phase 2 948
Phase 2/3 540
Phase 3 1763
Relapsed/refractory (n 5 19)
Phase 1 197
Phase 1/2 333
Phase 2 760
Phase 3 1652
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lead to duplicative analyses, a concern that has been addressed
by prior research.6-9,58,59 With the approval of FLT3 inhibitors
midostaurin and gilteritinib for newly diagnosed and relapsed/refractory
AML, it is likely that more FLT3-mutant patients will receive FLT3
inhibitors that are not part of an investigational trial. Loosening
inclusion and exclusion criteria that limits prior exposure to a FLT3
inhibitor could be a way to enhance enrollment numbers. An
alternative approach would be to deploy alternative measures to
determine effectiveness. The US Food and Drug Administration has
provided some guidance by encouraging clinical investigators to
develop minimum residual disease assays to be used as surrogates
in measuring clinical benefit.60 However, larger phase 3 studies are
still needed to evaluate meaningful clinical benefit through survival
measures, such as event-free survival or overall survival.
There might also be benefit from broader efforts in both adult and
pediatric oncology to enhance the supply of patients for clinical trial
participation. In 2018, the National Cancer Institute loosened
eligibility requirements for patients with brain metastases, HIV/AIDs,
organ dysfunction, prior or current malignancies, and those younger
than 18 years.61 This move was supported by additional pro-
fessional organizations, such as the American Society of Clini-
cal Oncology and Friends of Cancer Research. Promotion of
the Children’s Oncology Group has resulted in 90% to 95% of
pediatric patients 15 years old or younger receiving care from
Children’s Oncology Group-affiliated institutions, with 50% to 60%
of trial-eligible children treated on a study protocol if one is
available.62,63 Pediatric patients diagnosed with acute lymphoblas-
tic leukemia have seen great benefit from these collaborative
initiatives, with cure rates rising from 10% to 90% since the 1960s,
evidence that collective efforts to include and treat individuals on
such protocols is promising.64 Improved clinical trial enrollment with
the intent of improving cancer outcomes has been adopted in adult
clinical trials in the United Kingdom as well. In 1999, survival rates
were poor when compared with other European Union members,
and clinical trial accrual was less than 3.5% of incident cases.61
There have been higher adult participation rates in clinical trials
since implementation of the National Health Service Cancer Plan
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Figure 3. Recruitment needs vs clinical trial participation rates at 1%, 3%, 5%, and 10% reflected by the green, yellow, gray, and red bars, respectively. This
graph represents trials that accrued in the United States, internationally, and in the United States 1 internationally (A); in the United States and/or the United States 1 internationally
(B); or in the United States only (C). The period reflects trials that were completed and/or enrolling between 2000 and 2017.
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and Cancer Networks in the United Kingdom, where participation is
as high as 12% of annual incident cases.65
The inability to successfully accrue subjects to clinical trials may
lead to unpublished scientific findings and research data.8,9,26
Noncompletion of a clinical study can result in exposure of patients
to investigational agents without thorough investigation into the
benefits or adverse events this may elicit.26 Our findings have
prompted supply-side suggestions for increasing clinical trial
participation. However, it is worth considering the structure of
demand as well. Statistical rigor of phase 2 and 3 clinical trials
could be altered to increase acceptable false-positive rates or
choose 1-sided instead of 2-sided tests. Phase 1 and 2 trials
could concurrently examine efficacy and toxicity. This might
represent too large a risk. Alternatively, more rigorous phase
1 and 2 trials could result in only the most beneficial results moving
toward larger phase 3 trials. However, one could argue that the
production of multiple drugs targeting similar pathways or
mutations at any stage of development is good, in that it promotes
competition among drug companies, ultimately leading to cheaper
drugs for the patient.
Clinical trial conduct and enrollment in the United States is
a complex issue without a clear fix. Investment in past and present
trends is a promising start. “Venture philanthropy” has incentivized
industry and federal partnerships by sharing financial risk, contrib-
uting to shortened translational processes and a focus on “human
return.”66 Partnerships between foundations and academic institu-
tions have also improved early development by enhancing access
both to patients for clinical trial participation and disease specialists
for study design consultation.66 For example, growth of the Multiple
Myeloma Research Consortium has led to standardized language
for clinical trial agreements to allow for multisite integration and
further investment and input from industry-led trials.66 The Multiple
Myeloma Research Consortium represents partnerships among
industry, the US Food and Drug Administration, and the Multiple
Myeloma Research Foundation.66 Another method is to work within
existing precompetitive public-private partnerships or to advocate
for the formation of new partnerships.67 Public-private partnerships
offer a groundwork for governmental, university, patient organiza-
tions/foundations, and industry collaboration.67 Last, umbrella or
basket/master trials allow the opportunity for treatment assignment
on the basis of genetic, molecular, cellular, or immune markers,
creating a “funneled” screening approach that can increase patient
participation and “fit.”68 This again requires flexible partnerships
among regulatory agencies, pharmaceutical industries, genomic
testing, and academic and clinical sites.68 Examples of umbrella and
basket/master trials are the National Cancer Institute Match trial, the
TAPUR trial, the Lung-MAP trial, and the Beat AML master trial.68
Encouraging and facilitating ongoing collaboration and partnerships
across disciplines is a promising effort to enhance clinical trial
participation for patients with FLT3-mutant AML and other
malignancies.
Limitations of our study
Systematic review and data extraction were performed by a single
person, and are therefore subject to human error. The graphical
representations for subgroup analysis are based on US incidence
counts only and do not consider the incidence of AML in each
international location. In addition, US incidence counts do not
include the relapsed/refractory AML population.
Accrual duration was calculated using study start date and primary
completion date, where the primary completion date represents the
date of data collection for primary endpoint measures. Although it is
the most consistently reported measure on ClinicalTrials.gov, study
accrual can end before primary completion date, and therefore the
duration of accrual could potentially be shorter for many of the
included studies. All calculations were made with the assumption
that accrual rate has been constant over the course of the trial; this
does not account for instances in which accrual varies drastically
between years. Our data collection methodology does not account
for patients who may have enrolled on multiple therapeutic studies
for the treatment of AML, particularly early-phase studies, with
targeted or nonspecific agents. This may occur in both FLT3
inhibitor trials and trials of other targeted agents. We anticipate this
to be a relatively small patient population, as early-phase studies are
available at a limited number of cancer centers. More specific to
FLT3 inhibitor trials, we note that before the approval of midostaurin
in 2017, some FLT3 inhibitor studies would not allow patients with
prior FLT3 inhibitor exposure or prior treatment to enroll on new
FLT3-targeted trials (eg, NCT01657682), thus making it difficult
for a patient to be on multiple FLT3 inhibitor studies. However,
inclusion and exclusion criteria were amended in several such
studies after FLT3 inhibitors were added as standard of care (eg,
NCT02421939).
There is also the possibility of discrepancies in the incidence data
from literature publications vs the Centers for Disease Control and
Prevention, as mathematical projections could have differed. The
use of incidence data alone does not account for relapsed and
refractory patients and underestimates a potential pool of patients
with FLT3 AML eligible for clinical trials. However, the prevalence
data on patients with relapsed or refractory AML are not easily
available, and the preliminary analysis indicates that the number of
patients with relapsed and refractory FLT3 AML may be quite
small after accounting for remission rate, relapse rate, and overall
survival.
In addition, 1%, 3%, and 5% accrual is mostly based on solid tumor
data. Patients with AML and hematologic malignancy may be seen
more often at academic centers, and may have a higher proportion
of accrual. Rates of 1%, 3%, and 5% represent accrual to clinical
trials with primary locations in the United States. It could be
argued that subject recruitment needed beyond the available
patient population in the United States would require international
participation to reach projected accrual numbers.
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